<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000320</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-10068-1</org_study_id>
    <secondary_id>R01-10068-1</secondary_id>
    <nct_id>NCT00000320</nct_id>
  </id_info>
  <brief_title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1</brief_title>
  <official_title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare subject response to liquid vs. tablet formulations,
      to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate
      if dose response curve for tablet is equal to liquid form.&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) Compare subjects response to liquid vs tablet formulation 2) Assess bioequivalency of
      liquid vs tablet 3)Compare subject preference 4) Evaluate if dose response curve for tablet =
      to liquid form
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">August 1999</completion_date>
  <primary_completion_date type="Actual">August 1999</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood level</measure>
    <time_frame>across study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>drug use</measure>
    <time_frame>across study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>craving</measure>
    <time_frame>across study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>withdrawal symptoms</measure>
    <time_frame>across study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1; liquid formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2; tablet formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine formulation: liquid vs. tablet</intervention_name>
    <description>random assignment to liquid buprenorphine or tablet buprenorphine</description>
    <arm_group_label>1; liquid formulation</arm_group_label>
    <arm_group_label>2; tablet formulation</arm_group_label>
    <other_name>Subutex</other_name>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        M/F ages 18-65. Meet DMS-IV criteria for opiate dependence. Agree to conditions of the
        study and sign informed consent.

        Exclusion Criteria:

        Pregnant or nursing women. Acute medical condition that would interfere with study
        participation or put safety of subjects in jeopardy. Current daily use of anti-convulsants,
        antabuse or neuroleptics. DSM-IV diagnosis of ETOH or sedative/hypnotics dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 1999</study_first_submitted>
  <study_first_submitted_qc>September 20, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 1999</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Walter Ling, M.D.</name_title>
    <organization>Friends Research Institute</organization>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

